首页> 美国卫生研究院文献>Immunology >The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-α accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo
【2h】

The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-α accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo

机译:泛趋化因子抑制剂NR58-3.14.3消除了体内脂多糖诱导的肿瘤坏死因子-α积累和白细胞募集

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chemokines participate in the regulation of leucocyte recruitment in a wide variety of inflammatory processes, including host defence and diseases such as asthma, atherosclerosis and autoimmune disorders. We have previously described the properties of Peptide 3, the first broad-specificity chemokine inhibitor in vitro. Here, we report the properties of NR58-3.14.3, a retroinverso analogue of Peptide 3. NR58-3.14.3 inhibited leucocyte migration induced by a range of chemokines, including monocyte chemoattractant protein-1 (MCP-1) (2·5 nm), macrophage inflammatory protein-1α (MIP-1α) (5 nm), regulated on activation, normal T-cell expressed and presumably secreted (RANTES) (20 nm), stromal cell-derived factor-1α (SDF-1α) (25 nm) and interleukin-8 (IL-8) (30 nm), but did not affect migration induced by N-formyl-methionyl-leucyl-phenylalanine (FMLP) or complement C5a (> 100 µm). NR58-3.14.3 is therefore ≈1000-fold more potent than Peptide 3 but retains the broad-spectrum chemokine inhibitory activity of the parent peptide. In vivo, pretreatment with a systemic dose of 10 mg of NR58-3.14.3, but not the inactive derivative NR58-3.14.4, abolished leucocyte recruitment in response to intradermal injection of 500 ng of MCP-1 into rat skin. This suggests that NR58-3.14.3 is a functional chemokine inhibitor in vivo as well as in vitro. We utilized NR58-3.14.3 as a tool to investigate the role of chemokine activity during leucocyte recruitment in response to lipopolysaccharide (LPS) in vivo. NR58-3.14.3, but not NR58-3.14.4, abolished leucocyte recruitment in response to intradermal injection of 50 ng of LPS into rat skin. Furthermore, NR58-3.14.3 completely inhibited LPS-induced accumulation of tumour necrosis factor-α (TNF-α). This data is consistent with a model in which multiple chemokines act in parallel upstream of TNF-α. NR58-3.14.3 is therefore a powerful anti-inflammatory agent in vivo, suppressing proinflammatory cytokine production and leucocyte recruitment in response to endotoxin stimulus in rat skin.
机译:趋化因子在多种炎症过程中参与白细胞募集的调节,包括宿主防御和疾病,例如哮喘,动脉粥样硬化和自身免疫性疾病。我们先前已经描述了肽3的特性,肽3是体外第一种宽特异性趋化因子抑制剂。在这里,我们报告了NR58-3.14.3(肽3的逆反类似物)的特性。NR58-3.14.3抑制了一系列趋化因子(包括单核细胞趋化蛋白1(MCP-1))诱导的白细胞迁移(2·5 nm),巨噬细胞炎性蛋白1α(MIP-1α)(5 nm),受激活调节,正常T细胞表达和推测分泌(RANTES)(20 nm),基质细胞衍生因子1α(SDF-1α) (25 nm)和白介素8(IL-8)(30 nm),但不影响N-甲酰基-甲硫基-亮氨酰-苯丙氨酸(FMLP)或补体C5a(> 100 µm)引起的迁移。因此,NR58-3.14.3的效力比肽3约强1000倍,但保留了母体肽的广谱趋化因子抑制活性。在体内,以10毫克全身剂量的NR58-3.14.3进行预处理,而不是无活性的衍生物NR58-3.14.4进行的预处理,由于对大鼠皮肤内皮内注射500 ng MCP-1而取消了白细胞募集。这表明NR58-3.14.3在体内和体外都是功能性趋化因子抑制剂。我们利用NR58-3.14.3作为工具来研究趋化因子活性在白细胞募集期间响应体内脂多糖(LPS)的作用。 NR58-3.14.3(而非NR58-3.14.4)取消了白细胞募集,这是由于向大鼠皮肤皮内注射了50 ng LPS所致。此外,NR58-3.14.3完全抑制LPS诱导的肿瘤坏死因子-α(TNF-α)的积累。该数据与其中多个趋化因子在TNF-α的上游并行作用的模型一致。因此,NR58-3.14.3是一种强大的体内抗炎药,可抑制内源性刺激刺激大鼠皮肤中促炎性细胞因子的产生和白细胞募集。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号